XML 43 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Derivative Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]  
Schedule of Fair Values of the Company's Derivative Instruments and the Line Items on the Consolidated Balance Sheets

The fair values of the Company’s derivative instruments and the line items on the consolidated balance sheets to which they were recorded were summarized as follows:

 

 

 

Balance Sheet

 

 

 

 

 

 

 

 

 

Balance Sheet

 

 

 

 

 

 

 

 

 

 

Location

 

December 31,

2021

 

 

December 31,

2020

 

 

Location

 

December 31,

2021

 

 

December 31,

2020

 

 

 

 

 

(In thousands)

 

 

 

 

(In thousands)

 

Derivatives not designated as hedging instruments

 

Prepaid expenses and other current assets

 

$

1,214

 

 

$

324

 

 

Other accrued liabilities

 

$

321

 

 

$

2,344

 

Derivatives designated as hedging instruments

 

Prepaid expenses and other current assets

 

 

158

 

 

 

 

 

Other accrued liabilities

 

 

23

 

 

 

38

 

Total

 

 

 

$

1,372

 

 

$

324

 

 

 

 

$

344

 

 

$

2,382

 

 

Schedule of Company's Derivative Instruments on Accumulated Other Comprehensive Income and the Consolidated Statement of Operations

The effects of the Company’s derivative instruments on AOCI and the consolidated statements of operations were summarized as follows:

 

 

 

Year Ended December 31, 2019

 

 

 

2021

 

 

2020

 

 

2019

 

 

 

(In thousands)

 

Derivatives designated as hedging instruments:

 

 

 

 

 

 

 

 

 

 

 

 

Cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency forward contracts:

 

 

 

 

 

 

 

 

 

 

 

 

Gains (losses) recognized in accumulated other comprehensive income (loss) - Effective Portion

 

$

668

 

 

$

(856

)

 

$

1,565

 

Gains (losses) reclassified from accumulated other comprehensive income (loss) into income - Effective Portion (1):

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

459

 

 

$

(954

)

 

$

1,929

 

Cost of revenue

 

$

(2

)

 

$

2

 

 

$

(12

)

Research and development

 

$

31

 

 

$

9

 

 

$

(57

)

Sales and marketing

 

$

(30

)

 

$

124

 

 

$

(284

)

General and administrative

 

$

(5

)

 

$

27

 

 

$

(41

)

Derivatives not designated as hedging instruments:

 

 

 

 

 

 

 

 

 

 

 

 

Gains (losses) recognized in Other income (expenses), net

 

$

4,195

 

 

$

(3,861

)

 

$

1,307

 

 

(1)

Refer to Note 9, Stockholders’ Equity, in Notes to Consolidated Financial Statements, which summarizes the accumulated other comprehensive income (loss) activity related to derivatives.